Symbollon Pharmaceuticals, Inc. (SYMBA)

Symbollon Pharmaceuticals, Inc. (formerly Symbollon Corporation) was formed to develop and commercialize proprietary iodine-based products for infection control and treatment in biomedical and bioagricultural industries.

The success of future operations is subject to a number of risks similar to those of other companies in the same stage of development. Principal among these risks are the Company's cumulative operating losses, no assurance of profitable future operations, early state of market development, competition from substitute products or larger companies, dependence on key personnel and the uncertainty of additional future financing as needed.

Our financial statements for the year ended December 31, 2006 have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of our company as a going concern. We had a net loss of $3,046,784 and $3,138,065 and negative cash flows from operations of $1,779,530 and $2,609,491 for the year ended December 31, 2006 and nine months ended September 30, 2007, respectively. At December 31, 2006 and September 30, 2007, we also had an accumulated deficit of $15,858,535 and $18,996,600, respectively. These factors raise substantial doubt as to our ability to continue as a going concern.